17th Jun 2016 06:23
LONDON (Alliance News) - Technology investor Imperial Innovations Group PLC on Friday said its Cell Medica portfolio company has signed a partnership agreement with the Baylor College of Medicine in Houston, Texas.
Cell Medica, a UK-based cellular immunotherapy company in which Imperial holds a 27% stake, will partner with Baylor College on developing new immunotherapy products for cancer treatment.
The partnership is anticipated to deliver a significant number of new products for Cell Medica's pipeline and will provide Cell Medica with an exclusive licence over several Baylor cell and gene technologies, plus an option to licence new products introduced into the co-development partnership.
"This new agreement accelerates Cell Medica's ambitious growth plans and significantly broadens its cellular immunotherapy pipeline and US footprint. It is an important step forward in its strategy to become a world-leader in cell therapy, leveraging its scientific and manufacturing base," said Imperial Innovations Chief Executive Russ Cummings.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Imperial Innovations Group